Lexicon extends intellectual property portfolio with patent on gene trapping.Lexicon Genetics, Inc. (The Woodlands, TX) announced the issuance of United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. Patent 6,776,988 (the "988 patent") entitled "Vectors for gene mutagenesis mutagenesis /mu·ta·gen·e·sis/ (mu?tah-jen´e-sis)1. the production of change. 2. the induction of genetic mutation. mu·ta·gen·e·sis n. pl. and gene discovery." The 988 patent is Lexicon's seventh related to its proprietary gene trapping technology. The 988 patent covers cells that have been genetically engineered genetically engineered adjective Recombinant, see there using Lexicon's third-generation gene trapping constructs. The newly-issued patent covers the substantial majority of the more than 270,000 embryonic stem cell Embryonic stem cells (ES cells) are stem cells derived from the inner cell mass of an early stage embryo known as a blastocyst. Human embryos reach the blastocyst stage 4-5 days post fertilization, at which time they consist of 50-150 cells. ES cells are pluripotent. clones present in Lexicon's OmniBank library and identified by DNA sequence DNA sequence Genetics The precise order of bases–A,T,G,C–in a segment of DNA, gene, chromosome, or an entire genome. See Base pair, Base sequence analysis, Chromosome, Gene, Genome. in Lexicon's OmniBank database. The patent also covers the cells of knockout mice and other model organisms containing genetic modifications that were made using the technology. Lexicon scientists use gene knockout technology -- both gene trapping and gene targeting -- to systematically discover the physiological functions of genes to identify potential points of therapeutic intervention, or drug targets. Lexicon has a pipeline of more than 40 drug discovery programs that resulted from discoveries made using these patented technologies. Lexicon is a biopharmaceutical company focused on the discovery of breakthrough treatments for human disease. Lexicon is systematically discovering the physiological and behavioral functions of genes to identify potential points of therapeutic intervention, or drug targets. Lexicon makes these discoveries using its proprietary gene knockout technology to model the physiological effects that could be expected from prospective drugs directed against novel targets. The company has advanced knockout-validated targets into drug discovery programs in six therapeutic areas: diabetes and obesity, cardiovascular disease Cardiovascular disease Disease that affects the heart and blood vessels. Mentioned in: Lipoproteins Test cardiovascular disease , cancer, immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. disorders, ophthalmic disease, and psychiatric and neurological disorders. Lexicon is working both independently and through strategic collaborations and alliances to accelerate the development and commercialization of its discoveries. Lexicon Genetics, Inc. +1-281-863-3503 www.lexicon-genetics.com |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion